Arrowstreet Capital’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Arrowstreet Capital’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-65	Closed	-$22K	–	2230
2019 Q4	$22K	Sell	65 -67	-51%	-$30.7K	﹤0.01%	1697
2019 Q3	$66K	Buy	+132	New	+$74.5K	﹤0.01%	1517
2019 Q2	–	Sell	-948	Closed	-$578K	–	1863
2019 Q1	$578K	Buy	948 +431	+83%	+$235K	﹤0.01%	1454
2018 Q4	$189K	Buy	+517	New	+$278K	﹤0.01%	1258

Other funds holding NBRV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

FNC

First National Corp Rockland, Massachusetts $527M AUM 12.33% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VFA

Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Arrowstreet Capital's NBRV Position: Q1 2020 in Review

Arrowstreet Capital sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2020, closing a stake of 65 shares — an estimated $22K sold.

Arrowstreet Capital first reported a position in NBRV in Q4 2018 and held it in 4 quarters. The position peaked at $578K in Q1 2019. 50 funds tracked by Wall St. Rank hold NBRV as of Q1 2020.

Arrowstreet Capital reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2020 after selling out during the quarter.
Arrowstreet Capital sold 65 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2020, an estimated $22K.
Arrowstreet Capital first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2018 and held it in 4 quarters.
Arrowstreet Capital's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $578K in Q1 2019.
50 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2020.

Based on Arrowstreet Capital's 13F filing for Q1 2020, filed 15 May 2020.